Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS | 18 | 22 | -1,06 % | ||
| BIONTECH | 14 | 13 | +1,96 % | ||
| SPYRE THERAPEUTICS | 12 | 3 | +24,43 % | ||
| REVOLUTION MEDICINES | 11 | 5 | +35,22 % | ||
| REPLIMUNE | 10 | 1 | -61,77 % | ||
| ALLOGENE THERAPEUTICS | 6 | 6 | +39,89 % | ||
| IDEAYA BIOSCIENCES | 5 | 3 | +16,26 % | ||
| TEMPUS AI | 4 | 1 | +5,97 % | ||
| ORUKA THERAPEUTICS | 4 | - | 0,00 % | ||
| CARIS LIFE SCIENCES | 4 | - | +7,19 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:59 | Allogene Therapeutics Stock Surges 49% On Positive CAR-T Trial Data | - | RTTNews | ||
| 16:48 | Allogene jumps on analysis of phase 2 data for B-cell lymphoma asset cema-cel | 5 | Seeking Alpha | ||
| 16:42 | Regeneron, Telix Enter Strategic Radiopharma Collaboration | 3 | Contract Pharma | ||
| 16:38 | Eilmeldung am Abend: BIONTECH SE ADR zündet Kursrakete! | 4 | Maximilian Berger | ||
| 16:30 | Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday | 2 | Benzinga.com | ||
| 16:27 | Revolution Medicines surges 38% on pancreatic cancer breakthrough | 6 | iNVEZZ.com | ||
| 16:26 | Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda's Entyvio | 3 | FierceBiotech | ||
| 16:18 | Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo | 5 | Benzinga.com | ||
| 15:58 | TD Cowen senkt Kursziel für Caris Life Sciences aufgrund von Bewertungsanpassung | 1 | Investing.com Deutsch | ||
| 15:54 | Baird raises Allogene stock price target to $9 on clinical data | 2 | Investing.com | ||
| 15:54 | TD Cowen cuts Caris Life Sciences stock price target on valuation | 3 | Investing.com | ||
| 15:42 | TD Cowen reiterates Halozyme stock Buy rating on royalty growth | 1 | Investing.com | ||
| 15:42 | Spyre stock maintains Buy rating at Stifel on UC trial data | 1 | Investing.com | ||
| 15:36 | Genmab A/S: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer | 150 | Business Wire | Phase 1/2 RAINFOL-01 data showed the combination of rinatabart sesutecan (Rina-S) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The... ► Artikel lesen | |
| 15:36 | Revolution Medicines surges on data for pancreatic cancer asset daraxonrasib | 3 | Seeking Alpha | ||
| 15:35 | REVOLUTION MEDICINES - Biotech-Aktie zündet nach Studiendaten nächste Rallystufe | 8 | stock3.com | ||
| 15:34 | Goldman Sachs bestätigt Rating für Spyre Therapeutics nach positiven Studiendaten | 1 | Investing.com Deutsch | ||
| 15:30 | Goldman Sachs reiterates Early-Stage Biotech on Spyre stock | 2 | Investing.com | ||
| 15:18 | Leerink reiterates Spyre stock rating on positive trial data | 1 | Investing.com | ||
| 15:07 | Guggenheim reiterates Spyre stock Buy rating after trial results | 2 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.